ReutersCodex · 实盘不做把握 6/10
北京时间·🕒 发布 02:20:36时区推断·⟳ 抓取 02:25:52·⚡ 决策 07-16 02:32:23 +6m31s·103.7 天前
美敦力Covidien疝气补片首个陪审团示范审判开庭，约万名类似原告待决
这是美敦力（MDT.US）Covidien疝气补片诉讼的首个bellwether trial开庭，方向偏负面但目前只是开庭而非败诉、和解或赔偿金额落地。
📄 原文Reuters↗ 原文
Medical device manufacturer Medtronic (MDT.N) went on trial on Wednesday in the first case to reach a jury out of thous…
不做 美敦力（MDT.US）
方向偏空但只是诉讼开庭，尚无败诉、赔偿或和解金额，且MDT.US为千亿美元市值公司、盘中未负向反应；做空催化不够强，不开空，可考虑降低相关医疗器械多头敞口。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 律师网站此前已写明Covidien首个MDL bellwether trial定于2026-07-13开始并持续约4周，说明排期风险并非今日才出现。
- Reuters报道美敦力Covidien疝气补片首个陪审团示范审判开庭，约10350名类似原告仍在推进。市场反应:MDT.US在18:31 UTC报价80.88美元，较前收上涨1.99%。
关键理由
- 这是美敦力（MDT.US）Covidien疝气补片诉讼的首个bellwether trial开庭，方向偏负面但目前只是开庭而非败诉、和解或赔偿金额落地。
- 美敦力当前市值约1038亿美元，单一产品责任诉讼在未有裁决金额前难以形成可量化的短线市值级冲击。
- 股价在事件抓取时盘中上涨1.99%，未显示市场把该开庭新闻作为即时重大利空重定价。
主要风险
- 若未来陪审团给出高额惩罚性赔偿或推动大规模和解，诉讼负债预期可能重新定价。
- 同类疝气补片诉讼已有较大行业和解案例，当前不做空不等于否认后续负面尾部风险。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-07-15 · 影响 weakens
未看到已裁决、已和解或披露赔偿金额；当前仅为开庭，做空催化强度不足。
检索:Medtronic Covidien hernia mesh first bellwether trial settlement verdict July 2026 原文 ↗
工具调用 · 历史记录,结果未知(1 种)
- stock_quote · 结果未知
原文全文
展开原文 · 3,274 字
Medical device manufacturer Medtronic (MDT.N) went on trial on Wednesday in the first case to reach a jury out of thousands of lawsuits by people who claim they were injured by defective hernia-repair mesh implants made by its Covidien unit.
Lawyers for the company and an Alabama resident who was implanted with Covidien-made mesh in 2017 sparred before a federal jury in Boston over whether the product was to blame for his injuries, in a so-called bellwether trial that could help shape the outcome of similar lawsuits facing Medtronic.
About 10,350 other plaintiffs nationally are pursuing similar claims against Medtronic alleging they were harmed after being implanted with products from hernia lines that include Parietex, ProGrip and Symbotex.
Other hernia mesh manufacturers have faced similar cases, most of which have settled. Most of the cases against Medtronic are in Massachusetts, where about 7,450 plaintiffs have pending lawsuits in state court. Another 2,400 lawsuits are consolidated in federal multidistrict litigation before U.S. District Judge Patti Saris, who is presiding over the trial that started Wednesday.
The plaintiff, Larry Patterson, was implanted with a Symbotex mesh during a 2017 hernia repair operation and claims it eventually caused him to suffer a bowel obstruction necessitating another operation in 2020.
Timothy O’Brien, a lawyer for Patterson at Levin, Papantonio, Proctor, Buchanan, O’Brien, Barr & Mougey, in his opening statement told jurors that doctors including Patterson's surgeon were never warned about a potential risk posed by a key safety feature of Covidien's polyester mesh.
That safety feature is a collagen coating that is intended to act as a barrier and prevent bare polyester mesh from being exposed to intestines while abdominal lining regrows. Symbotex's coating was made from pig, a shift from the past use of bovine collagen.
O'Brien said that sales staff told doctors the coating would last for 30 days as had been the experience with bovine collagen, but the company knew that the porcine collagen would be absorbed in seven days, which for Patterson and other patients was not enough time to avoid complications.
"No one will darken that door, come into court, and say we told Larry Patterson's surgeon it will go away in a week and he implanted it anyway," O'Brien said.
Lyn Pruitt, a lawyer for Medtronic at DLA Piper, countered that the coating worked as designed. She urged jurors to question whether other factors could have led to Patterson's injury, which she noted occurred three years after the mesh was implanted.
She argued the evidence would show that the mesh was not what caused Patterson's bowel obstruction but that he had suffered a hernia recurrence, which he was at increased risk of developing as a result of surgical decisions and factors such as obesity and diabetes.
“I want you to know this design did what it is supposed to do," Pruitt said.
The trial is expected to last three to four weeks.
The case is Patterson v. Covidien Inc, U.S. District Court for the District of Massachusetts, No. 1:22-cv-10153.
For the plaintiff: Timothy O’Brien of Levin, Papantonio, Proctor, Buchanan, O’Brien, Barr & Mougey
For Medtronic: Lyn Pruitt of DLA Piper
Lawyers for the company and an Alabama resident who was implanted with Covidien-made mesh in 2017 sparred before a federal jury in Boston over whether the product was to blame for his injuries, in a so-called bellwether trial that could help shape the outcome of similar lawsuits facing Medtronic.
About 10,350 other plaintiffs nationally are pursuing similar claims against Medtronic alleging they were harmed after being implanted with products from hernia lines that include Parietex, ProGrip and Symbotex.
Other hernia mesh manufacturers have faced similar cases, most of which have settled. Most of the cases against Medtronic are in Massachusetts, where about 7,450 plaintiffs have pending lawsuits in state court. Another 2,400 lawsuits are consolidated in federal multidistrict litigation before U.S. District Judge Patti Saris, who is presiding over the trial that started Wednesday.
The plaintiff, Larry Patterson, was implanted with a Symbotex mesh during a 2017 hernia repair operation and claims it eventually caused him to suffer a bowel obstruction necessitating another operation in 2020.
Timothy O’Brien, a lawyer for Patterson at Levin, Papantonio, Proctor, Buchanan, O’Brien, Barr & Mougey, in his opening statement told jurors that doctors including Patterson's surgeon were never warned about a potential risk posed by a key safety feature of Covidien's polyester mesh.
That safety feature is a collagen coating that is intended to act as a barrier and prevent bare polyester mesh from being exposed to intestines while abdominal lining regrows. Symbotex's coating was made from pig, a shift from the past use of bovine collagen.
O'Brien said that sales staff told doctors the coating would last for 30 days as had been the experience with bovine collagen, but the company knew that the porcine collagen would be absorbed in seven days, which for Patterson and other patients was not enough time to avoid complications.
"No one will darken that door, come into court, and say we told Larry Patterson's surgeon it will go away in a week and he implanted it anyway," O'Brien said.
Lyn Pruitt, a lawyer for Medtronic at DLA Piper, countered that the coating worked as designed. She urged jurors to question whether other factors could have led to Patterson's injury, which she noted occurred three years after the mesh was implanted.
She argued the evidence would show that the mesh was not what caused Patterson's bowel obstruction but that he had suffered a hernia recurrence, which he was at increased risk of developing as a result of surgical decisions and factors such as obesity and diabetes.
“I want you to know this design did what it is supposed to do," Pruitt said.
The trial is expected to last three to four weeks.
The case is Patterson v. Covidien Inc, U.S. District Court for the District of Massachusetts, No. 1:22-cv-10153.
For the plaintiff: Timothy O’Brien of Levin, Papantonio, Proctor, Buchanan, O’Brien, Barr & Mougey
For Medtronic: Lyn Pruitt of DLA Piper
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。